Published in Proc Natl Acad Sci U S A on February 04, 2005
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Advancing translational research with the Semantic Web. BMC Bioinformatics (2007) 4.38
Structural classification of toxic amyloid oligomers. J Biol Chem (2008) 4.16
Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano (2008) 3.88
Matrix-insensitive protein assays push the limits of biosensors in medicine. Nat Med (2009) 3.58
Gold nanoparticles in chemical and biological sensing. Chem Rev (2012) 3.51
Drivers of biodiagnostic development. Nature (2009) 3.28
Maximizing DNA loading on a range of gold nanoparticle sizes. Anal Chem (2006) 2.86
The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest (2005) 2.51
Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A (2009) 2.50
Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc Natl Acad Sci U S A (2009) 2.33
Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med (2008) 1.90
Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A (2008) 1.84
Soluble Aβ oligomer production and toxicity. J Neurochem (2011) 1.83
Beta-amyloid modulation of synaptic transmission and plasticity. J Neurosci (2007) 1.68
Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain (2013) 1.64
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem (2011) 1.63
Amyloid beta-protein toxicity and the pathogenesis of Alzheimer disease. J Biol Chem (2008) 1.57
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol (2009) 1.47
Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener (2013) 1.44
Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol (2012) 1.44
A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol (2009) 1.44
Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease. PLoS One (2010) 1.41
Microarray methods for protein biomarker detection. Analyst (2008) 1.40
Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.38
Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis (2010) 1.33
Aβ oligomer-induced synapse degeneration in Alzheimer's disease. Cell Mol Neurobiol (2011) 1.33
Gold nanoparticles: preparation, properties, and applications in bionanotechnology. Nanoscale (2011) 1.32
Amyloid-β-induced synapse damage is mediated via cross-linkage of cellular prion proteins. J Biol Chem (2011) 1.29
Peptide antisense nanoparticles. Proc Natl Acad Sci U S A (2008) 1.23
New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Alzheimers Dement (2013) 1.22
Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering. Nat Nanotechnol (2014) 1.18
Emerging nanotechnology-based strategies for the identification of microbial pathogenesis. Adv Drug Deliv Rev (2009) 1.16
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol (2015) 1.11
Nanoparticle self-assembly gated by logical proteolytic triggers. J Am Chem Soc (2007) 1.11
Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. PLoS One (2010) 1.10
Nanoparticles for detection and diagnosis. Adv Drug Deliv Rev (2009) 1.08
Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicol Appl Pharmacol (2009) 1.08
Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med (2012) 1.07
CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr Biol (Camb) (2011) 1.03
Nanoparticles and their applications in cell and molecular biology. Integr Biol (Camb) (2014) 1.02
The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events. Front Neurosci (2015) 1.02
Sensitive detection of Aβ protofibrils by proximity ligation--relevance for Alzheimer's disease. BMC Neurosci (2010) 1.02
Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. PLoS One (2013) 1.01
Multipole plasmon resonances in gold nanorods. J Phys Chem B (2006) 1.00
Magnetic particles in ultrasensitive biomarker protein measurements for cancer detection and monitoring. Expert Opin Med Diagn (2011) 0.98
A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid. PLoS One (2013) 0.98
Electrophilic affibodies forming covalent bonds to protein targets. J Biol Chem (2009) 0.96
Transgenic Drosophila models of Alzheimer's disease and tauopathies. Brain Struct Funct (2009) 0.96
Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. PLoS One (2012) 0.96
"Smart" diblock copolymers as templates for magnetic-core gold-shell nanoparticle synthesis. Nano Lett (2010) 0.96
Single bead affinity detection (SINBAD) for the analysis of protein-protein interactions. PLoS One (2008) 0.95
Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease. Nat Nanotechnol (2014) 0.94
CSF Biomarkers for Alzheimer's Disease Diagnosis. Int J Alzheimers Dis (2010) 0.94
High-sensitivity nanosensors for biomarker detection. Chem Soc Rev (2011) 0.93
Abeta oligomers and fibrillar aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures. Biophys J (2009) 0.93
Gold Nanoparticles for In Vitro Diagnostics. Chem Rev (2015) 0.92
Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon. Prim Care Companion J Clin Psychiatry (2007) 0.91
Colorimetric Cu(2+) detection using DNA-modified gold-nanoparticle aggregates as probes and click chemistry. Small (2010) 0.91
Progress on RNAi-based molecular medicines. Int J Nanomedicine (2012) 0.90
Ultrasensitive and highly selective detection of Alzheimer's disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticle. ACS Nano (2009) 0.90
Nonenzymatic detection of bacterial genomic DNA using the bio bar code assay. Anal Chem (2007) 0.89
Amyloid-β(1-42) protofibrils formed in modified artificial cerebrospinal fluid bind and activate microglia. J Neuroimmune Pharmacol (2012) 0.89
Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. J Alzheimers Dis (2010) 0.89
Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease. Front Cell Neurosci (2015) 0.89
Nanoscience enables ultrasensitive detection of Alzheimer's biomarker. Proc Natl Acad Sci U S A (2005) 0.87
Translational actomyosin research: fundamental insights and applications hand in hand. J Muscle Res Cell Motil (2012) 0.87
Clioquinol and other hydroxyquinoline derivatives inhibit Abeta(1-42) oligomer assembly. Neurosci Lett (2009) 0.87
Alzheimer's disease: pathological mechanisms and recent insights. Curr Neuropharmacol (2011) 0.86
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. Alzheimers Res Ther (2014) 0.86
RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivity. PLoS One (2009) 0.85
Sensitive detection of protein and miRNA cancer biomarkers using silicon-based photonic crystals and a resonance coupling laser scanning platform. Lab Chip (2013) 0.85
Nanodevices in diagnostics. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.84
Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there? Expert Rev Neurother (2006) 0.84
Two types of nanoparticle-based bio-barcode amplification assays to detect HIV-1 p24 antigen. Virol J (2012) 0.84
Expression and localization of mitochondrial ferritin mRNA in Alzheimer's disease cerebral cortex. PLoS One (2011) 0.84
Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. Front Neurol (2015) 0.84
Advances on the understanding of the origins of synaptic pathology in AD. Curr Genomics (2007) 0.83
Detection and Identification of Bioanalytes with High Resolution LSPR Spectroscopy and MALDI Mass Spectrometry. J Phys Chem C Nanomater Interfaces (2009) 0.83
Nano-biosensors to detect beta-amyloid for Alzheimer's disease management. Biosens Bioelectron (2016) 0.82
Antibodies covalently immobilized on actin filaments for fast myosin driven analyte transport. PLoS One (2012) 0.82
Design of β-amyloid aggregation inhibitors from a predicted structural motif. J Med Chem (2012) 0.82
Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. Nanomedicine (2015) 0.82
Potential applications of magnetic particles to detect and treat Alzheimer's disease. Nanoscale Res Lett (2014) 0.81
Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. Biochim Biophys Acta (2016) 0.80
Fish-on-a-chip: a sensitive detection microfluidic system for Alzheimer's disease. J Biomed Sci (2011) 0.80
Large size fibrillar bundles of the Alzheimer amyloid beta-protein. Eur Biophys J (2007) 0.79
Integration of biosensors and drug delivery technologies for early detection and chronic management of illness. Sensors (Basel) (2013) 0.79
Purified high molecular weight synthetic Aβ(1-42) and biological Aβ oligomers are equipotent in rapidly inducing MTT formazan exocytosis. Neurosci Lett (2011) 0.79
Toward Epileptic Brain Region Detection Based on Magnetic Nanoparticle Patterning. Sensors (Basel) (2015) 0.78
Citrus bergamia Juice Extract Attenuates β-Amyloid-Induced Pro-Inflammatory Activation of THP-1 Cells Through MAPK and AP-1 Pathways. Sci Rep (2016) 0.78
RNA aptamer probes as optical imaging agents for the detection of amyloid plaques. PLoS One (2014) 0.78
Ultrasensitive measurement of protein and nucleic Acid biomarkers for earlier disease detection and more effective therapies. Biotechnol Healthc (2006) 0.78
Post-genomics nanotechnology is gaining momentum: nanoproteomics and applications in life sciences. OMICS (2014) 0.77
The Role of Insulin and Insulin-Like Growth Factor-1/FoxO-Mediated Transcription for the Pathogenesis of Obesity-Associated Dementia. Curr Gerontol Geriatr Res (2012) 0.77
A window into the heterogeneity of human cerebrospinal fluid Aβ peptides. J Biomed Biotechnol (2011) 0.77
A microfluidic detection system based upon a surface immobilized biobarcode assay. Biosens Bioelectron (2008) 0.77
Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Alzheimers Res Ther (2010) 0.77
The Role of Reactive Oxygen Species (ROS) in the Biological Activities of Metallic Nanoparticles. Int J Mol Sci (2017) 0.76
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
Pathways towards and away from Alzheimer's disease. Nature (2004) 8.72
Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science (2003) 8.17
Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.51
Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med (2000) 6.72
Scanometric DNA array detection with nanoparticle probes. Science (2000) 6.12
CSF markers for incipient Alzheimer's disease. Lancet Neurol (2003) 6.12
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A (2003) 4.80
Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA (2003) 4.16
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol (2003) 3.75
What controls the melting properties of DNA-linked gold nanoparticle assemblies? J Am Chem Soc (2003) 3.45
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol (2001) 3.19
Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging (2002) 3.09
Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry (2003) 2.85
Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl (1998) 2.83
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 2.74
The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol Aging (1997) 2.72
Bio-bar-code-based DNA detection with PCR-like sensitivity. J Am Chem Soc (2004) 2.14
Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol (2003) 1.98
Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology (1997) 1.78
CSF biomarkers for mild cognitive impairment. J Intern Med (2004) 1.56
Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. J Mol Neurosci (2003) 1.12
Alzheimer's disease: treatments in discovery and development. Nat Neurosci (2002) 1.06
Molecular imaging: Bridging the gap between neuroradiology and neurohistology. Histol Histopathol (2004) 0.89
Accuracy of CT scan measurements of the medial temporal lobe in routine dementia diagnostics. Int J Geriatr Psychiatry (2003) 0.87
[Spectral analysis of EEG coherence in Alzheimer's disease]. Rev Neurol (2004) 0.86
Nanostructures in biodiagnostics. Chem Rev (2005) 9.96
Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science (2003) 8.17
Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science (2006) 6.42
Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci (2007) 6.27
DNA-programmable nanoparticle crystallization. Nature (2008) 6.24
Nanoparticles with Raman spectroscopic fingerprints for DNA and RNA detection. Science (2002) 6.14
Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci (2004) 5.10
Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A (2003) 4.80
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
Array-based electrical detection of DNA with nanoparticle probes. Science (2002) 4.33
Gold nanoparticles for biology and medicine. Angew Chem Int Ed Engl (2010) 4.14
Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol (2010) 4.04
Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol (2002) 3.84
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med (2005) 3.46
What controls the melting properties of DNA-linked gold nanoparticle assemblies? J Am Chem Soc (2003) 3.45
Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem (2007) 3.35
Drivers of biodiagnostic development. Nature (2009) 3.28
Nanoparticle superlattice engineering with DNA. Science (2011) 3.27
Gene regulation with polyvalent siRNA-nanoparticle conjugates. J Am Chem Soc (2009) 3.17
Applications of dip-pen nanolithography. Nat Nanotechnol (2007) 3.02
Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2005) 2.97
Protein nanoarrays generated by dip-pen nanolithography. Science (2002) 2.95
Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res (2002) 2.88
Maximizing DNA loading on a range of gold nanoparticle sizes. Anal Chem (2006) 2.86
Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry (2003) 2.85
On-wire lithography. Science (2005) 2.81
Nanotechnologies for biomolecular detection and medical diagnostics. Curr Opin Chem Biol (2006) 2.74
Oligonucleotide loading determines cellular uptake of DNA-modified gold nanoparticles. Nano Lett (2007) 2.68
Nano-flares: probes for transfection and mRNA detection in living cells. J Am Chem Soc (2007) 2.67
Multiplexed detection of protein cancer markers with biobarcoded nanoparticle probes. J Am Chem Soc (2006) 2.64
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Colorimetric detection of mercuric ion (Hg2+) in aqueous media using DNA-functionalized gold nanoparticles. Angew Chem Int Ed Engl (2007) 2.52
Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A (2009) 2.50
The evolution of dip-pen nanolithography. Angew Chem Int Ed Engl (2004) 2.49
Polyvalent DNA nanoparticle conjugates stabilize nucleic acids. Nano Lett (2009) 2.46
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2007) 2.43
Physical discipline and children's adjustment: cultural normativeness as a moderator. Child Dev (2005) 2.39
Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem (2005) 2.36
Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron (2010) 2.34
Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc Natl Acad Sci U S A (2009) 2.33
An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. J Clin Invest (2012) 2.33
Controlling anisotropic nanoparticle growth through plasmon excitation. Nature (2003) 2.33
Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell (2013) 2.32
Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem (2006) 2.32
The role radius of curvature plays in thiolated oligonucleotide loading on gold nanoparticles. ACS Nano (2009) 2.32
Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J (2007) 2.25
A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci (2010) 2.22
Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc (2005) 2.21
Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. J Am Chem Soc (2009) 2.16
Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci (2003) 2.14
Polymer pen lithography. Science (2008) 2.14
Bio-bar-code-based DNA detection with PCR-like sensitivity. J Am Chem Soc (2004) 2.14
A thermodynamic investigation into the binding properties of DNA functionalized gold nanoparticle probes and molecular fluorophore probes. J Am Chem Soc (2005) 2.12
Localized surface plasmon resonance spectroscopy of single silver triangular nanoprisms. Nano Lett (2006) 2.10
Designing, fabricating, and imaging Raman hot spots. Proc Natl Acad Sci U S A (2006) 2.10
Spherical nucleic acids. J Am Chem Soc (2012) 2.09
Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging (2007) 1.99
Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med (2013) 1.99
Rationally designed nanostructures for surface-enhanced Raman spectroscopy. Chem Soc Rev (2008) 1.98
DNA-nanoparticle superlattices formed from anisotropic building blocks. Nat Mater (2010) 1.92
Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci U S A (2012) 1.90
Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles. Bioconjug Chem (2010) 1.85
Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann Neurol (2002) 1.82
Multiple thiol-anchor capped DNA-gold nanoparticle conjugates. Nucleic Acids Res (2002) 1.80
Nanogap-engineerable Raman-active nanodumbbells for single-molecule detection. Nat Mater (2009) 1.78
TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys. Cell Metab (2013) 1.74
Observation of a quadrupole plasmon mode for a colloidal solution of gold nanoprisms. J Am Chem Soc (2005) 1.73
Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci (2006) 1.69
Highly uniform and reproducible surface-enhanced Raman scattering from DNA-tailorable nanoparticles with 1-nm interior gap. Nat Nanotechnol (2011) 1.69
Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem (2006) 1.67
Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci (2006) 1.66
Coordination polymers from silver(I) and bifunctional pyridyl ligands. Inorg Chem (2005) 1.65
Parent discipline practices in an international sample: associations with child behaviors and moderation by perceived normativeness. Child Dev (2010) 1.65
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem (2011) 1.63
Spectroscopic tracking of molecular transport junctions generated by using click chemistry. Angew Chem Int Ed Engl (2009) 1.62
Self-assembly of mesoscopic metal-polymer amphiphiles. Science (2004) 1.61
Asymmetric functionalization of gold nanoparticles with oligonucleotides. J Am Chem Soc (2006) 1.59
Aptamer nano-flares for molecular detection in living cells. Nano Lett (2009) 1.58
Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropathol Exp Neurol (2006) 1.56
Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res (2008) 1.56
Molecular printing. Nat Chem (2009) 1.56
Raman dye-labeled nanoparticle probes for proteins. J Am Chem Soc (2003) 1.53
Mechanism for the endocytosis of spherical nucleic acid nanoparticle conjugates. Proc Natl Acad Sci U S A (2013) 1.53
Activation of caspase-6 in aging and mild cognitive impairment. Am J Pathol (2007) 1.53
Gas-sorption properties of cobalt(II)--carborane-based coordination polymers as a function of morphology. Small (2009) 1.52
A modular microfluidic architecture for integrated biochemical analysis. Proc Natl Acad Sci U S A (2005) 1.52
A coordination chemistry dichotomy for icosahedral carborane-based ligands. Nat Chem (2011) 1.52
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res (2008) 1.51